AST-120: Completed Phase IIb enrollment

Ocera completed enrollment of 150 patients in the double-blind, placebo-controlled, U.S. Phase IIb ASTUTE trial evaluating 2 or 4 grams oral AST-120 given thrice daily for up to 8 weeks. Ocera license...